Trial Profile

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin for extensive disease small cell lung cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amrubicin (Primary) ; Carboplatin (Primary) ; Irinotecan (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

24 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network record (UMIN000008970).
12 Oct 2012 New source identified and integrated (University Hospital Medical Information Network record UMIN000008970).
24 Sep 2012 Status changed from not yet recruiting to recruiting according to the University Hospital Medical Information Network record (UMIN000008970).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com